[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Icecure Medical Ltd Ord (ICCM)

Icecure Medical Ltd Ord (ICCM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 24,460
  • Shares Outstanding, K 81,180
  • Annual Sales, $ 3,380 K
  • Annual Income, $ -15,060 K
  • EBIT $ -4 M
  • EBITDA $ -15 M
  • 60-Month Beta 0.47
  • Price/Sales 6.87
  • Price/Cash Flow N/A
  • Price/Book 2.31
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.24
  • Most Recent Earnings $-0.06 on 03/17/26
  • Next Earnings Date 05/27/26 [--]
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical Services

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.03
  • Number of Estimates 1
  • High Estimate $-0.03
  • Low Estimate $-0.03
  • Prior Year $-0.06
  • Growth Rate Est. (year over year) +50.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2525 +19.33%
on 04/28/26
0.3831 -21.35%
on 04/20/26
+0.0003 (+0.10%)
since 04/01/26
3-Month
0.2525 +19.33%
on 04/28/26
0.7368 -59.11%
on 03/16/26
-0.3098 (-50.70%)
since 01/30/26
52-Week
0.2525 +19.33%
on 04/28/26
1.4000 -78.48%
on 10/03/25
-0.8587 (-74.03%)
since 05/01/25

Most Recent Stories

More News
IceCure Participates in Society of Breast Imaging Symposium 2026 as U.S. ProSense® Revenue Increases by 30%+ in First Quarter of 2026 Compared to First Quarter of 2025

The Company's participation at the Society of Breast Imaging Symposium and other upcoming medical conferences are timely as commercial momentum accelerates

ICCM : 0.3013 (+5.35%)
IceCure Announces Pricing of $4.0 Million Registered Direct Offering and Concurrent Private Placement

CAESAREA, Israel , March 26, 2026 /PRNewswire/ -- IceCure Medical Ltd . (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology...

ICCM : 0.3013 (+5.35%)
IceCure Reports Positive 5-Year Top-Line Results from ICESECRET Kidney Cancer Cryoablation Study: 89.4% and 83.9% Recurrence-Free Rates

At a median follow-up of four years, 89.4% recurrence-free rate in patients with tumors ≤3 cm and no prior kidney cancer; 83.9% recurrence-free rate for general study population

ICCM : 0.3013 (+5.35%)
IceCure Appoints Meir Peleg as Chief Financial Officer

Meir Peleg brings over 20 years of financial leadership and experience including with Nasdaq listed companies

ICCM : 0.3013 (+5.35%)
IceCure Reports 2025 Full Year Financial & Operational Results

Record 4 th quarter and full year sales of $1.3 million and $3.4 million, respectively

ICCM : 0.3013 (+5.35%)
U.S. FDA Approves IceCure's Post-Marketing "ChoICE" Study for ProSense® Cryoablation in the Local Treatment of Low-Risk Breast Cancer

IceCure is engaged with leading medical institutions throughout the U.S. looking to participate in the post-market study with the FDA-cleared ProSense®

ICCM : 0.3013 (+5.35%)
IceCure Medical to Report 2025 Full Year Financial and Operating Results on March 17, 2026

CAESAREA, Israel , March 10, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology...

ICCM : 0.3013 (+5.35%)
American Society of Breast Surgeons (ASBrS) Resource Guide Update Recommends Cryoablation for Low-Risk Breast Cancer

IceCure's ICE3 study and the FDA Advisory Panel's favorable vote on ProSense® cryoablation's benefit-risk profile for low-risk breast cancer played a key role in the ASBrS 2026 Resource Guide update

ICCM : 0.3013 (+5.35%)
IceCure Medical Reports Independent Study Published in PLOS One Demonstrating ProSense® Cryoablation Safe and Effective in Treatment of Breast Fibroadenomas

Treatment with ProSense® resulted in 92.9% volume reduction of fibroadenoma one-year post-cryoablation

ICCM : 0.3013 (+5.35%)
IceCure Medical Successfully Completes 5-Year Patient Follow Up in ICESECRET Kidney Cancer Cryoablation Study: Final Analysis Expected in Second Quarter of 2026

Previously released interim data from 111 patients demonstrated ProSense® is safe and effective in destruction of kidney tumors with 88.7% recurrence-free rate

ICCM : 0.3013 (+5.35%)

Business Summary

IceCure Medical Ltd. develops and markets an advanced liquid-nitrogen-based cryoablation therapy for the treatment of tumors by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. IceCure Medical Ltd. is based in CAESAREA, Israel.

See More

Key Turning Points

3rd Resistance Point 0.3584
2nd Resistance Point 0.3426
1st Resistance Point 0.3219
Last Price 0.3013
1st Support Level 0.2854
2nd Support Level 0.2696
3rd Support Level 0.2489

See More

52-Week High 1.4000
Fibonacci 61.8% 0.9617
Fibonacci 50% 0.8262
Fibonacci 38.2% 0.6908
Last Price 0.3013
52-Week Low 0.2525

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.